SLNO vs. FEMY, IMVT, SOLV, PEN, STVN, IRTC, BLCO, GKOS, TMDX, and NVST
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical" sector.
Soleno Therapeutics vs. Its Competitors
Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.
In the previous week, Soleno Therapeutics had 11 more articles in the media than Femasys. MarketBeat recorded 13 mentions for Soleno Therapeutics and 2 mentions for Femasys. Femasys' average media sentiment score of 0.64 beat Soleno Therapeutics' score of 0.36 indicating that Femasys is being referred to more favorably in the media.
Femasys currently has a consensus price target of $7.33, indicating a potential upside of 853.62%. Soleno Therapeutics has a consensus price target of $115.92, indicating a potential upside of 75.78%. Given Femasys' higher possible upside, equities analysts plainly believe Femasys is more favorable than Soleno Therapeutics.
Femasys has a beta of -2.64, indicating that its share price is 364% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, indicating that its share price is 375% less volatile than the S&P 500.
Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.
Femasys has higher earnings, but lower revenue than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.
65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Soleno Therapeutics beats Femasys on 10 of the 17 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLNO) was last updated on 10/16/2025 by MarketBeat.com Staff
